Back to top
more

Selecta Biosciences, Inc. (SELB)

(Delayed Data from NSDQ)

$2.35 USD

2.35
240,236

+0.23 (10.85%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.36 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Cartesian Therapeutics, Inc. [SELB]

Reports for Purchase

Showing records 1 - 20 ( 35 total )

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

08/18/2023

Company Report

Pages: 5

Pipeline Programs Pared; 2Q23 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

05/08/2023

Company Report

Pages: 5

SEL-212 Approaches Filing; Restructuring to Reduce Costs; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/22/2023

Company Report

Pages: 8

SEL-212 DISSOLVE Program Meets Primary Endpoints; Raising PT to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

03/07/2023

Company Report

Pages: 7

SEL-212 Pivotal Data Nears; Pipeline Expands; 2022 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

12/16/2022

Company Report

Pages: 4

IgA Nephropathy Program Candidate Unveiled; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

11/07/2022

Company Report

Pages: 7

DISSOLVE Readouts Approaching; 3Q22 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

09/26/2022

Industry Report

Pages: 48

Biotechnology - Ever Evolving Genetic Medicines

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

08/22/2022

Company Report

Pages: 8

DISSOLVE Program Nearing Conclusion; 2Q22 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

06/21/2022

Company Report

Pages: 5

Sarepta Agreement Expanded; DISSOLVE Program Advancing; Lowering PT to $4

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

01/11/2022

Company Report

Pages: 5

Additional Partnership Inked With Ginkgo Bioworks; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

12/02/2021

Company Report

Pages: 4

DISSOLVE I Study Completes Patient Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

11/29/2021

Company Report

Pages: 5

Clinical Hold Reaction Appears Excessive; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

11/15/2021

Company Report

Pages: 5

ImmTOR Gene Vector Data Appears Promising; 3Q21 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

11/01/2021

Company Report

Pages: 6

Partnership Inked With Ginkgo Bioworks; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

10/22/2021

Company Report

Pages: 5

Strategic Licensing Agreement Inked With Genovis; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

10/05/2021

Company Report

Pages: 5

Strategic Licensing Agreement Inked With Takeda; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for SELB

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

09/09/2021

Company Report

Pages: 5

Cyrus Biotechnology Collaboration Agreement Announced; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

09/02/2021

Company Report

Pages: 5

SEL-399 Data Next Quarter; 2Q21 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cartesian Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

07/27/2021

Company Report

Pages: 5

Publication Underscores ImmTOR Tolerability and Efficacy; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party